HiTMab - Monoclonal Antibody Discovery Solutions
Single cell B-cell receptor sequencing is used to identify paired heavy and light chain combination for antibodies against targets of interest, thus generating a large repertoire of monoclonal antibodies more efficiently than the hybridoma technology. MedGenome’s HiTMab (High-throughput monoclonal antibody discovery) platform based on its proprietary single cell genomics technology enables identification of multiple antigen specific B cells against a target.
In this whitepaper, we discuss the features of HitMab in speeding up the discovery of validated antibodies.
Advanced Single cell analysis: MedGenome’s bioinformatic approach
Single-cell (sc) related sequencing allows the study of biological samples at a unique high resolution. While sample sequencing with these technologies is getting more streamlined, the downstream analysis and interpretation of the generated data remains a challenge.
This whitepaper explores how MedGenome has been integrating streamlined workflows following best practices that are widely adopted by the scientific community.
MedGenome's TCR repertoire profiling solutions
The Whitepaper discusses TCR repertoire profiling using bulk input (from cells, RNA and FFPE tissue) using the SMARTerTCR Profiling Kit (Takara Bio USA Inc) and single-cell inputs using the SMARTer single-cell TCR Profiling kit and the Chromium Immune Profiling solutions (10X Genomics). We have tested and optimized the commercially available library preparation methods to work for a wide range of input types to obtain TCR alpha, beta, gamma & delta clonotypes (for bulk), and TCR alpha and beta clonotypes from single-cell inputs.
Epigenomic profiling solutions at MedGenome
MedGenome Inc.’s Monoclonal Antibody Discovery Services
Antibody discovery is important for early stage research studies, diagnostics and therapeutics. Hybridoma technology has been the mainstay to generate monoclonal antibodies. MedGenome has streamlined antibody discovery using high-throughput single B cell receptor sequencing and a recently licensed proprietary platform, HiTMab* (High-throughput monoclonal antibody discovery).
MedGenome Inc. Services with Illumina’s TruSight Oncology 500 (TSO 500)
Illumina’s TSO 500 is a comprehensive assay that enables comprehensive genomic profiling of tumor samples. It is a single workflow identifying DNA and RNA variants from the same sample. It can detect InDels, SNVs, CNV, fusions and splice variants. It also measures biomarkers like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) using limited sample input. MedGenome uses propriety analysis pipeline along with Illumina’s Basespace platform to analyze data providing high sensitivity and specificity to provide a comprehensive cancer genomic profile.
Comprehensive single-cell genomic applications for multi-omic analysis
Single cell genomics is a powerful approach to uncover cellular heterogeneity and understand molecular mechanisms of development and disease in normal and disease tissues. MedGenome has several options for single cell NGS processing. In this whitepaper, we highlight various workflows to help decide the best approach for your samples and scientific questions.
Denovo Genome Assembly Solutions at MedGenome
The Whitepaper explores MedGenome's experience in genomics technologies in developing a comprehensive, customizable service for high-quality genome assembly and annotation.
MedGenome Inc. Broadens NGS offerings with Loop Genomics Metagenomics Service
The whitepaper discusses how MedGenome utilizes Loop Genomics technology for 16S long-read sequencing that covers the entire V1-V9 regions in a single read that are classified at the species or genus level, with zero false-positive assignments.
Human B-cell Receptor Profiling service at MedGenome Inc.
Human Bulk BCR Profiling Technical Sheet
At MedGenome, we provide BCR repertoire profiling from bulk input (from cells & RNA) using the SMARTer BCR Profiling Kit (Takara Bio USA Inc) and single-cell inputs using the Chromium Immune Profiling solutions (10X Genomics). The sample types we have validated include frozen PBMCs, hybridoma and spleen. We follow the manufacturers recommended guidelines for our quality control at every step of the process and provide customers with accurate QC reports. In addition, we support experimental design and basic and advanced analysis.
TCR sequencing solutions at MedGenome
In this whitepaper, we present MedGenome’s NGS based workflows for profiling of the TCR repertoire: namely a) Bulk TCR profiling using: SMARTer TCR α /β Profiling Kit (Takara Bio USA Inc) and modifications to the protocol for Gamma/Delta and FFPE TCR repertoire profiling, b) Single cell TCR Profiling using: 10X Genomics Chromium Immune Profiling solutions, and Takara single-cell TCR sequencing kits. We also present an overview of the types of samples we have processed in-house and application.
T Cell Receptor (TCR) Repertoire Sequencing
In this technical sheet, we present information on the workflows for TCR sequencing at MedGenome and also present the sample types that we can process. We also present application data using SMARTer TCR α/β Profiling Kit and 10x Genomics chromium platform downstream of neoantigen vaccine screening platform developed at MedGenome : OncoPeptVAC.
T Cell Receptor (TCR) repertoire sequencing from FFPE samples
In this white-paper we present data generated by using a modified protocol of the SMARTer® TCR Proﬁling Kit to perform TCR sequencing and analysis of tumor-infiltrating lymphocytes (TILs) from a FFPE tumor tissue block.
We accept sample both as RNA (100 ng minimum) or 5 μm unstained FFPE tumor tissue blocks.
OncoPeptTUMETM — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications
Cancer immunotherapy is now established as a major therapeutic modality, and 70% of all cancer patients are estimated to receive some form of immunotherapy treatment as a part of their disease control by 2025. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated patients by activating CD8 T-cells and provide sustainable and long-lasting benefit in a few. Recently significant efforts have been devoted to understanding the factors that influence response to immuno-therapy or contribute to the development of resistance to therapy. While it is appreciated that many different tumor cell- intrinsic and extrinsic features, including the tumor microenvironment, driver gene mutations, host genetics, microbiome and environmental factors modulate response to immune checkpoint inhibitors , the tumor microenvironment ecosystem could be a major contributor in regulating response to immunotherapy and development of resistance [2,3].